Firefly Neuroscience Partners with Department of Defense for PTSD Assessment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Should l Buy AIFF?
Firefly Neuroscience announced a partnership with the Department of War to support the assessment and treatment of active-duty U.S. service members and veterans suffering from Post-Traumatic Stress Disorder and/or Traumatic Brain Injury. The genesis of this public-private brain health partnership was initial work by the founders of Evoke Neuroscience with the U.S. Naval Medical Center Camp Lejeune Family Medicine Residency program. Specific details of the partnership and related programs remain confidential in accordance with applicable agreements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AIFF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AIFF
About AIFF
Firefly Neuroscience, Inc. is an artificial intelligence (AI) company advancing precision neuroscience. The Company's BNA Platform and Evoke System are Class II medical devices, which were cleared by FDA for commercialization. The Company's FDA-510(k) cleared Evoke System, commercially deployed as the Evoke System, is in active use over 85 clinical sites in the United States. The Company has developed Firefly Platform, a vertically integrated hardware, software, and data infrastructure that captures standardized electroencephalographic (EEG) and event-related potential (ERP) assessments at the point of care, analyzes that data through its proprietary analytics engine, and delivers structured, clinician-ready reports back to the provider, all within a single seamless workflow. Its proprietary analytics engine analyzes raw EEG and ERP signals across captured dimensions and compares each patient’s electrophysiological profile to a reference dataset.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Firefly Neuroscience Partners with Department of War for AI-Driven PTSD Treatment
- Strategic Partnership: Firefly Neuroscience Inc. has entered into an agreement with the Department of War to deploy its AI-driven EEG/ERP platform aimed at evaluating and treating active-duty personnel and veterans suffering from PTSD and traumatic brain injuries, marking a significant advancement in military health initiatives.
- Addressing Health Challenges: This initiative focuses on leveraging advanced brain-monitoring technology to tackle persistent health challenges faced by military personnel, which is expected to significantly enhance the mental health and quality of life for service members and veterans.
- Research Foundation: The collaboration builds on earlier research conducted with a U.S. Naval Medical Center program, laying the groundwork for broader adoption of this technology across military healthcare systems, demonstrating its feasibility and effectiveness.
- Positive Market Reaction: Following the announcement, Firefly Neuroscience's stock surged over 20% in Thursday's premarket trading, reflecting investor optimism regarding the company's prospects in the medical technology sector.
See More
Firefly Neuroscience Inc. Forms Partnership with Department of Defense for PTSD and TBI Initiatives
Partnership Announcement: Firefly Neuroscience has announced a partnership with the Department of War for the development of programs related to PTSD and TBI.
Focus on Mental Health: The collaboration aims to address mental health issues, particularly post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI), through innovative neuroscience solutions.
See More
FIREFLY ANNOUNCES COLLABORATION WITH THE DEPARTMENT OF WAR IN PUBLIC-PRIVATE PARTNERSHIP
Partnership Announcement: Firefly has confirmed a partnership with the Department of War, indicating a collaboration in public-private initiatives.
Focus on Innovation: The partnership aims to leverage innovative solutions to enhance operational efficiency and effectiveness within the Department of War.
Strategic Goals: The collaboration is expected to align with strategic goals that support national security and defense initiatives.
Future Developments: Further details on the specific projects and initiatives under this partnership are anticipated in upcoming announcements.
See More
Firefly Neuroscience's EEG Tech Enhances ADHD Diagnosis
- Technological Innovation: Firefly Neuroscience's EEG/ERP technology can analyze resting and cognitive EEG brain scans to identify patterns that differentiate hyperactive-impulsive, inattentive, and combined forms of ADHD, providing doctors with more accurate diagnostic support.
- Market Reaction: Following the announcement that its AI-powered technology could help identify ADHD subtypes, Firefly's stock soared approximately 50% on Friday, reaching its highest level in nearly five months, reflecting strong investor confidence in the technology's potential.
- Performance Growth: Since acquiring Evoke Neuroscience in May 2025, Firefly has increased EEG/ERP brain scan volumes by 33 times, and on March 4, the stock price surged 126%, showcasing a significant achievement with its commercial footprint expanding over 20-fold.
- Future Outlook: Firefly's acceptance into the NVIDIA Connect program aims to leverage NVIDIA's tools and resources to develop a foundational model of the human brain, with CEO Greg Lipschitz stating that the growing brain scan data and NVIDIA GPU acceleration will lead to further breakthroughs in cognitive brain biomarker discovery.
See More
Firefly Neuroscience Shares Surge 48% on ADHD Biomarker Discovery
- Breakthrough Discovery: Firefly Neuroscience announced a breakthrough in identifying new brain-wave biomarkers that may help distinguish between the three major subtypes of ADHD, leading to a stock price surge of over 48%.
- FDA-Cleared Platform: The findings stem from Firefly's FDA-cleared Evoke EEG/ERP platform, which employs AI to analyze brain signal patterns, providing a more objective method for ADHD diagnosis.
- Clinical Application Potential: The newly identified biomarkers will offer clinicians an objective tool to differentiate between hyperactive-impulsive, inattentive, and combined-type ADHD, thereby supporting more precise treatment decisions and medication selection.
- Long-Term Strategic Goal: Firefly's research also advances its broader goal of building a large-scale EEG/ERP 'brain functional model' trained on over 191,000 brain scans, enhancing its competitiveness in the neuroscience field.
See More
Firefly Neuroscience Shares Surge 43% on ADHD Biomarker Discovery
- Significant Stock Surge: Firefly Neuroscience, Inc. (AIFF) shares surged approximately 43% during Friday morning trading, currently priced at $2.50, up from an opening price of $1.90, reaching a high of $2.64, indicating strong market reaction to its recent announcement.
- Discovery of New Biomarkers: The company announced the discovery of new brain wave biomarkers for the differential diagnosis of ADHD, a breakthrough that will assist healthcare professionals in accurately identifying ADHD subtypes, thereby enabling more tailored treatment plans.
- Technological Application Potential: Utilizing the company's AI-powered EEG/ERP technology, health experts can more effectively determine treatment types and dosage decisions for patients, as well as monitor the effectiveness of interventions, enhancing the precision of ADHD treatment.
- Market Performance Analysis: Over the past year, AIFF's stock has fluctuated between $0.62 and $6.00, with the current price increase reflecting investor confidence in the company's growth potential, particularly in innovative applications within the ADHD sector.
See More
Firefly Neuroscience Partners with Department of War for AI-Driven PTSD Treatment
- Strategic Partnership: Firefly Neuroscience Inc. has entered into an agreement with the Department of War to deploy its AI-driven EEG/ERP platform aimed at evaluating and treating active-duty personnel and veterans suffering from PTSD and traumatic brain injuries, marking a significant advancement in military health initiatives.
- Addressing Health Challenges: This initiative focuses on leveraging advanced brain-monitoring technology to tackle persistent health challenges faced by military personnel, which is expected to significantly enhance the mental health and quality of life for service members and veterans.
- Research Foundation: The collaboration builds on earlier research conducted with a U.S. Naval Medical Center program, laying the groundwork for broader adoption of this technology across military healthcare systems, demonstrating its feasibility and effectiveness.
- Positive Market Reaction: Following the announcement, Firefly Neuroscience's stock surged over 20% in Thursday's premarket trading, reflecting investor optimism regarding the company's prospects in the medical technology sector.
See More
Firefly Neuroscience Inc. Forms Partnership with Department of Defense for PTSD and TBI Initiatives
Partnership Announcement: Firefly Neuroscience has announced a partnership with the Department of War for the development of programs related to PTSD and TBI.
Focus on Mental Health: The collaboration aims to address mental health issues, particularly post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI), through innovative neuroscience solutions.
See More
FIREFLY ANNOUNCES COLLABORATION WITH THE DEPARTMENT OF WAR IN PUBLIC-PRIVATE PARTNERSHIP
Partnership Announcement: Firefly has confirmed a partnership with the Department of War, indicating a collaboration in public-private initiatives.
Focus on Innovation: The partnership aims to leverage innovative solutions to enhance operational efficiency and effectiveness within the Department of War.
Strategic Goals: The collaboration is expected to align with strategic goals that support national security and defense initiatives.
Future Developments: Further details on the specific projects and initiatives under this partnership are anticipated in upcoming announcements.
See More
Firefly Neuroscience's EEG Tech Enhances ADHD Diagnosis
- Technological Innovation: Firefly Neuroscience's EEG/ERP technology can analyze resting and cognitive EEG brain scans to identify patterns that differentiate hyperactive-impulsive, inattentive, and combined forms of ADHD, providing doctors with more accurate diagnostic support.
- Market Reaction: Following the announcement that its AI-powered technology could help identify ADHD subtypes, Firefly's stock soared approximately 50% on Friday, reaching its highest level in nearly five months, reflecting strong investor confidence in the technology's potential.
- Performance Growth: Since acquiring Evoke Neuroscience in May 2025, Firefly has increased EEG/ERP brain scan volumes by 33 times, and on March 4, the stock price surged 126%, showcasing a significant achievement with its commercial footprint expanding over 20-fold.
- Future Outlook: Firefly's acceptance into the NVIDIA Connect program aims to leverage NVIDIA's tools and resources to develop a foundational model of the human brain, with CEO Greg Lipschitz stating that the growing brain scan data and NVIDIA GPU acceleration will lead to further breakthroughs in cognitive brain biomarker discovery.
See More
Firefly Neuroscience Shares Surge 48% on ADHD Biomarker Discovery
- Breakthrough Discovery: Firefly Neuroscience announced a breakthrough in identifying new brain-wave biomarkers that may help distinguish between the three major subtypes of ADHD, leading to a stock price surge of over 48%.
- FDA-Cleared Platform: The findings stem from Firefly's FDA-cleared Evoke EEG/ERP platform, which employs AI to analyze brain signal patterns, providing a more objective method for ADHD diagnosis.
- Clinical Application Potential: The newly identified biomarkers will offer clinicians an objective tool to differentiate between hyperactive-impulsive, inattentive, and combined-type ADHD, thereby supporting more precise treatment decisions and medication selection.
- Long-Term Strategic Goal: Firefly's research also advances its broader goal of building a large-scale EEG/ERP 'brain functional model' trained on over 191,000 brain scans, enhancing its competitiveness in the neuroscience field.
See More
Firefly Neuroscience Shares Surge 43% on ADHD Biomarker Discovery
- Significant Stock Surge: Firefly Neuroscience, Inc. (AIFF) shares surged approximately 43% during Friday morning trading, currently priced at $2.50, up from an opening price of $1.90, reaching a high of $2.64, indicating strong market reaction to its recent announcement.
- Discovery of New Biomarkers: The company announced the discovery of new brain wave biomarkers for the differential diagnosis of ADHD, a breakthrough that will assist healthcare professionals in accurately identifying ADHD subtypes, thereby enabling more tailored treatment plans.
- Technological Application Potential: Utilizing the company's AI-powered EEG/ERP technology, health experts can more effectively determine treatment types and dosage decisions for patients, as well as monitor the effectiveness of interventions, enhancing the precision of ADHD treatment.
- Market Performance Analysis: Over the past year, AIFF's stock has fluctuated between $0.62 and $6.00, with the current price increase reflecting investor confidence in the company's growth potential, particularly in innovative applications within the ADHD sector.
See More
